Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary Disease

NCT04206007 is registered in ClinicalTrials.gov with Meridigen Biotech Co., Ltd. as lead sponsor.

NCT NCT04206007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04206007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary Disease
Lead sponsor
Meridigen Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
June 11, 2020
Completion date
June 30, 2024
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease moderate